Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease
- Conditions
- Coronary Artery Disease
- Registration Number
- NCT01735305
- Lead Sponsor
- Shenyang Northern Hospital
- Brief Summary
Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years old who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were physician discretion.
- Detailed Description
Antiplatelet therapy is the cornerstone for the prevention of atherothrombosis in patients with coronary artery disease (CAD). However, the efficacy and safety of antiplatelet therapy are varied due to ethnic and/or individual variability. The aim of the OPT-CAD study was to demonstrate contemporary status and outcomes of antiplatelet therapy in Chinese CAD patients, and to explore predictors of ischemic or bleeding events in such cohort.Patients above 18 years who were diagnosed as CAD and received antiplatelet therapy were prospectively enrolled in this national wide, non-intervention registry. All medications and laboratory tests were at physician discretion.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14032
Not provided
- With severe disease and life expectancy for 6 months or less
- Difficult to attain follow-up situations judged by researchers (travel, speech or mental disorder, etc.)
- Taking part in an interventional clinical research
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse cardiac and cerebral events 12month a composite of all cause death, myocardial infarction, stroke or any revascularization or stroke
- Secondary Outcome Measures
Name Time Method all cause death 12month stroke 12 months Stent thrombosis 12 month by BARC definition
rehospitalization 12 month any rehospitalization for cardiac or noncardiac reasons
any bleeding events 12 month by BARC definition
myocardial infarction 12 months any revascularization 12 months recurrent angina 12 month
Trial Locations
- Locations (107)
The first affiliated hospital of Bengbu Medical College
🇨🇳Bengbu, Anhui, China
Beijing Anzhen Hospital
🇨🇳Beijing, Beijing, China
Navy General Hospital
🇨🇳Beijing, Beijing, China
The 304th Hospital of PLA
🇨🇳Beijing, Beijing, China
The 306th of PLA
🇨🇳Beijing, Beijing, China
The Luhe teaching hospital of the Capital Medical University
🇨🇳Beijing, Beijing, China
The People's Hospital of Beijing University
🇨🇳Beijing, Beijing, China
Yanshan hospital
🇨🇳Beijing, Beijing, China
Beijing Fuwai Hospital
🇨🇳Beijin, Beijing, China
Third Military Medical University Xinqiao Hospital
🇨🇳Chongqing, Chongqing, China
Scroll for more (97 remaining)The first affiliated hospital of Bengbu Medical College🇨🇳Bengbu, Anhui, China